Cutting-edge technologies are the driving force behind our research and vaccine development. Our innovative vaccine technology platform – AdVac® – offers real hope for the accelerated development of vaccines, and is designed to help the global health community better prepare for and combat life-threatening infectious disease outbreaks.[1]
This technology was used in the development of our Ebola vaccine regimen, which was approved by the European Commission in July 2020.[2], [3] The AdVac® technology was also used to construct our HIV, RSV and Zika vaccine candidates.[3]
The COVID-19 vaccine research programme is using Janssen’s AdVac® technology to help combat the current COVID-19 pandemic.[3]
AdVac® viral vector technology
Adenoviruses are a group of viruses that cause the common cold – so they are expert at transporting things into humans.[4]
Janssen’s AdVac® vectors are based on a specific type of adenovirus[5] that has been genetically modified so that it can no longer replicate in humans and cause disease.[6]


